RE:Increased Value Kingpin68 wrote: In this latest release, they did not state if the combination of R and the non cancer drug was better than R alone. Are the non cancer drugs just riding the coat tails of R ? Either way, the patents held by Theralase keep increasing in value many times over in my opinion. I think they will make it to approval, but even in a worst case scenario, the patent portfolio must be worth $1-$2 share, or more ?
It's a no brainer.
In the presented histogram, the first black bar represents a non-therapeutic control (placebo) having been added to Rutherrin, which is essentially using Rutherrin alone. The other white/black bar sets represent cell kill rates of drug "x" alone (white bars), followed by the cell kill rate after having added drug "x" to Rutherrin (designated by the black bars). When you compare the first black bar (Rutherrin alone) to the subsequent black bars, you can see that that each drug "x" gets a significant boost in cell kill rate that is more than additive (i.e. greater than the sum of the individual kill rates of using drug "x" and Rutherrin alone). There seems to be a "synergistic" increase in the cell kill rate, which makes this treatment option potential even more exciting, & that's "without" the use of light/radiation. This "greater than additive" effect of two drugs used together is the goal of any combo treatment. This is good news imo : )